Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.61 |
| ▸ | NOS1 | P29475 | 4/20 | 0.61 |
| ▸ | NOS3 | P29474 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8257196 | 0.90 | NOS2 (0.61) | NOS2NOS1NOS3LMNAKDM4E | |
| SCHEMBL4659793 | 0.90 | NOS2 (0.50) | NOS2NOS1NOS3LMNAKDM4E | |
| SCHEMBL4669485 | 0.88 | ALDH1A1 (0.57) | NOS2NOS1NOS3LMNAKDM4E | |
| SCHEMBL4635773 | 0.88 | NOS2 (0.62) | NOS2NOS1NOS3LMNAKDM4E | |
| SCHEMBL4635677 | 0.87 | NOS2 (0.63) | NOS2NOS1NOS3LMNAKDM4E | |
| SCHEMBL606031 | 0.86 | ALDH1A1 (0.55) | NOS2NOS1NOS3LMNAL3MBTL1 | |
| SCHEMBL605250 | 0.85 | LMNA (0.55) | NOS2NOS1NOS3LMNAKDM4E | |
| SCHEMBL4918724 | 0.85 | NOS2 (0.62) | NOS2NOS1NOS3LMNAKDM4E | |
| SCHEMBL11262208 | 0.84 | L3MBTL1 (0.51) | NOS2NOS1NOS3KDM4EL3MBTL1 | |
| SCHEMBL18547514 | 0.82 | CNR1 (0.56) | NOS2NOS1NOS3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| WO-2008119720-A1 | 1-(1-CYCLOBUTYL-4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119720-A1 | 1-(1-CYCLOBUTYL-4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| EP-1937670-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | CHRM1, CHRM2, CHRM4 | NOS2 2065/4885NOS1 1083/4885NOS3 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.